Table 3.
Mean dyspepsia score and SF-36 (mean (SEM)) at week 0 and week 4 in the three treatment groups
| Week 0 | Week 4 | p Value | |
| Mean dyspepsia score | |||
| Lansoprazole 30 mg | 21.7 (0.3) | 18.6 (0.4) | <0.001 |
| Lansoprazole 15 mg | 22.3 (0.4) | 19.0 (0.4) | <0.001 |
| Placebo | 22.1 (0.4) | 18.7 (0.5) | <0.001 |
| SF36-physical functioning | |||
| Lansoprazole 30 mg | 87.6 (1.1) | 87.0 (1.2) | NS |
| Lansoprazole 15 mg | 88.7 (1.2) | 85.6 (1.4) | 0.029 |
| Placebo | 88.6 (1.1) | 88.0 (1.2) | NS |
| SF36-role physical | |||
| Lansoprazole 30 mg | 58.7 (3.2) | 71.8 (6.1) | 0.027 |
| Lansoprazole 15 mg | 60.7 (2.9) | 61.5 (3.1) | NS |
| Placebo | 66.2 (3.0) | 75.3 (2.6) | 0.007 |
| SF36-bodily pain | |||
| Lansoprazole 30 mg | 55.2 (1.6) | 65.8 (1.6) | <0.001 |
| Lansoprazole 15 mg | 56.1 (1.7) | 64.4 (1.7) | <0.001 |
| Placebo | 56.6 (1.6) | 66.2 (1.8) | <0.001 |
| SF36-general health | |||
| Lansoprazole 30 mg | 46.5 (1.4) | 46.7 (1.5) | NS |
| Lansoprazole 15 mg | 45.1 (1.3) | 44.6 (1.4) | NS |
| Placebo | 45.5 (1.4) | 45.7 (1.6) | NS |
| SF36-vitality | |||
| Lansoprazole 30 mg | 53.0 (1.5) | 57.8 (1.5) | 0.004 |
| Lansoprazole 15 mg | 51.4 (1.5) | 53.6 (1.7) | NS |
| Placebo | 53.7 (1.4) | 54.7 (1.5) | NS |
| SF36-social function | |||
| Lansoprazole 30 mg | 55.2 (1.6) | 65.8 (1.6) | NS |
| Lansoprazole 15 mg | 56.1 (1.7) | 64.4 (1.7) | NS |
| Placebo | 56.6 (1.6) | 66.2 (1.8) | NS |
| SF36-role emotional | |||
| Lansoprazole 30 mg | 55.7 (3.5) | 62.9 (3.4) | 0.039 |
| Lansoprazole 15 mg | 55.5 (3.1) | 60.5 (3.3) | NS |
| Placebo | 59.6 (3.3) | 71.7 (3.1) | 0.001 |
| SF36-mental health | |||
| Lansoprazole 30 mg | 64.5 (1.2) | 66.5 (1.2) | NS |
| Lansoprazole 15 mg | 61.8 (1.3) | 63.6 (1.4) | NS |
| Placebo | 61.7 (1.4) | 64.9 (1.3) | 0.018 |